Article

Study: Magnetics Help Traumatic Brain Injury Headaches

Author(s):

Drugs have not been shown effective in relieving the debilitating headaches that can follow mild traumatic brain injury (MTBI). Researchers report that transcranial magnetic stimulation appears to do better.

Drugs have not been shown effective in relieving the debilitating headaches that can follow mild traumatic brain injury (MTBI)

In a study presented at the American Society of Interventional Pain Physicians meeting in Orlando, FL April 11, Robert McLay, MD, PhD and colleagues at the University of California San Diego and the Veterans Administration San Diego Healthcare System in La Jolla, CA, looked at the effects of repetitive transcranial magnetic stimulation (rTMS).

The treatment involves using a basic electromagnetic coupling principle in which a rapid discharge of electric current is converted into dynamic magnetic flux allowing the induction of a localized current in the brain. The idea is to achieve neuromodulation. The treatment has been used for treating other types of headaches.

The researchers treated 6 men with MTBI headaches. To be included in the study, they had to have headaches lasting more than 48 hours. Measured on a pain scale, the average intensity of these headaches was 5.50 before treatment and 2.67 after receiving rTMS.

In addition, headache intensity was reduced by an average of 53.05%, and the average headache exacerbation frequency was reduced by 78.97% with 2 patients reporting no more severe headaches.

The authors concede that randomized trials are needed to confirm their results but say their findings are encouraging.

“MTBI headaches are often treatment-resistant, but in this case series patients were found to have improvements in severity, frequency and duration of their headaches after rTMS,” they wrote in the abstract.

The authors had no conflicts to disclose.

Related Videos
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Kishore Iyer, MD , MBBS | Credit: Kishore Iyer on LinkedIn
Evan Dellon, MD, MPH | Credit: UNC Chapel Hill
Marlyn Mayo, MD | Credit: ACG
Kishore Iyer, MD, MBBS | Credit: Kishore Iyer on LinkedIn
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Bruce Sands, MD | Credit: Alimentiv
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
© 2024 MJH Life Sciences

All rights reserved.